Fig. 5. Comparable anti-tumor immunity induced by Compound 182 and the deletion of PTP1B or PTPN2 in T cells.

AT3-OVA mammary tumor cells were injected into the fourth inguinal mammary fat pads of 8-week-old C57BL/6 (n = 8–11 in each group), Lck-Cre;Ptp1b^fl/fl (C57BL/6) (n = 12) and Lck-Cre;Ptpn2^fl/fl (C57BL/6) (n = 14) female mice. Mice were treated with Compound 182 (CMP-182; 10 mg/kg i.v.; n = 8) or saline (n = 11) on days (d) 7, 9, 11, 13, 15, 17, 19, and 21 after tumor cell implantation. a Tumor growth was monitored and b tumor weights were measured. c–e Tumor-infiltrating lymphocytes (TILs) (CMP-182: n = 8; Saline: n = 7; Lck-Cre;Ptp1b^fl/fl: n = 8; Lck-Cre;Ptpn2^fl/fl: n = 8) including CD44^hiCD62L^lo CD8⁺ and CD4⁺ effector/memory (EM) T cells, CD19⁺ B cells, NK1.1⁺TCRβ⁻ (NK) cells, CD4⁺CD25⁺FoxP3⁺ regulatory T cells (T_regs) and granulocytic and monocytic CD11b⁺F4/80^hi/loLy6C⁺Ly6G^+/−myeloid-derived suppressor cells (MDSCs) were analyzed by flow cytometry. In (d) Tumor-infiltrating T cells were stimulated with PMA/Ionomycin in the presence of Golgi Stop/Plug and stained for intracellular IFN-γ and TNF. Intracellular granzyme B (GRZMB), surface PD-1 and TIM-3 were detected in unstimulated tumor-infiltrating CD8⁺ T cells. In (a–e) representative results (means ± SEM) from at least two independent experiments are shown. Significance for tumor sizes in (a) was determined using a 2-way ANOVA Test and for tumor weights in (b) and for TILs in (c–e) using a 1-way ANOVA Test. In (b, c, e) significances were determined using a 2-tailed Mann–Whitney U Test (^#p < 0.05, ^##p < 0.01, ^###p < 0.001) where indicated.